Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer

NARecruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

December 1, 2025

Conditions
Colorectal Cancer
Interventions
DRUG

FOLFOX , FOLFIRI or FOLFOXIRI regimens

FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle

DRUG

FOLFOX or CapeOX regimens

FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)

Trial Locations (1)

510000

RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER

collaborator

Sun Yat-sen University

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER